Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.53 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.53 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869978 | 0.82 | FAAH (0.53) | AVPR1AAVPR1BAVPR2MAPTTP53 | |
| SCHEMBL4863076 | 0.77 | MAPT (0.69) | AVPR1AMAPTPOLBTP53NPC1 | |
| SCHEMBL4868800 | 0.77 | MAPT (0.52) | MAPTPOLBTP53NPC1NFKB1 | |
| SCHEMBL4870695 | 0.77 | MAPT (0.52) | MAPTPOLBTP53NPC1NFKB1 | |
| SCHEMBL4868207 | 0.77 | AVPR1A (0.47) | AVPR1AAVPR1BAVPR2POLBTP53 | |
| SCHEMBL4871151 | 0.76 | MAPT (0.67) | AVPR1AMAPTPOLBTP53NPC1 | |
| SCHEMBL4871455 | 0.75 | POLB (0.47) | MAPTPOLBTP53NPC1NFKB1 | |
| SCHEMBL4870894 | 0.74 | POLB (0.54) | AVPR1AAVPR2MAPTPOLBTP53 | |
| SCHEMBL4861653 | 0.73 | NOTUM (0.48) | MAPTPOLBTP53NPC1NFKB1 | |
| SCHEMBL4863201 | 0.73 | POLB (0.58) | MAPTPOLBTP53NPC1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | AVPR1A 276/4885AVPR1B 189/4885AVPR2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.